Hi Chery,
I am reading some of the old emails and I have found this one. It talks
about the study of IFN Pegasys with Gleevec... What is the difference between
IFN alfa 2-b and Pegasys? As you know I am not the trial right now -
Gleevec+IFN+Leukine... so I wonder what is the difference between my trial and
the study below. Thank you. Livia
"[EMAIL PROTECTED]" <[EMAIL PROTECTED]> wrote:
Hi Kothai,
Actually, I was just at ASH and Dr. Hochhaus has presented his
findings from the trial he has been conducting over the last 6 years.
Additionally, I was at ASH with Jan from Germany who was one of the
patients in the study, and he is doing very well.
Here is the abstract:
28] Sustained Molecular Responses with Interferon 2a Maintenance
Therapy after Imatinib Plus IFN Induction Treatment for Chronic Phase
Chronic Myelogenous Leukemia. Session Type: Oral Session
Andreas Hochhaus, Andreas Neubauer, Martin C. Mueller, Simone
Napieralski, Philipp Erben, Tilman Bostel, Ruediger Hehlmann, Andreas
Burchert 3. Med. Klinik, Medizinische Fakultaet Mannheim, Universitaet
Heidelberg, Mannheim, Germany; Klinik f. Innere Medizin, Haematologie,
Onkologie und Immunologie, Universitaetsklinikum Giessen und Marburg,
Marburg, Germany
Most patients with chronic myelogenous leukemia (CML) relapse after
discontinuation of imatinib (IM, Glivec/Gleevec). Thus, current
recommendations suggest a lifelong IM therapy even in complete
molecular responders. However, in view of potential long term adverse
effects there is a concern of tyrosine kinase inhibition. Hence,
strategies to circumvent permanent kinase inhibitor therapy would be
of substantial clinical value. Interferon (IFN), in contrast to IM,
elicits an autologous antileukemic immune response to control CML, and
stopping IFN in complete cytogenetic responders is not associated with
relapse in a significant proportion of patients. We therefore sought
to determine efficacy and tolerability of an IFN maintenance
immunotherapy after IM/IFN induction in newly diagnosed chronic phase
CML patients. Twenty patients (14 m, 6 f; median age 44.6, range
23.5-74.1 years) have been investigated. Hasford score revealed low
(n=13), intermediate (n=6), and high risk (n=1) diseases. IM therapy
had been administered for 2.4 yrs (0.2-4.9), combined with PEG-IFN2a
(Pegasys, n=17) or IFN2a (Roferon, n=3). Maintenance therapy consisted
of PEG-IFN (n=16) or IFN (n=4). Dose was adjusted according to
response and tolerability and ranged between 135 g PEG-IFN every three
weeks to 180 g PEG-IFN once weekly week, or alternatively between 2 to
5*3 Mill IU IFN/week. IM was stopped due to side effects (n=5) or
after the patients individual request and informed consent (n=15). At
the time of imatinib withdrawal, 19 patients were in complete
cytogenetic remission and one patient did not show any cytogenetic
response. Major molecular response was determined in peripheral blood
leukocytes of 16 patients, including one patient with undetectable BCR-
ABL transcripts. After a median observation time of 1.2 yrs (range
0.1-3.1), 15 patients showed major molecular response, seven of them
were complete. Improvement of molecular response was observed in seven
and a stable situation in ten patients. By 6 weekly assessments of BCR-
ABL expression gradual molecular relapse was observed in three
patients. All relapsing patients responded to readministration of IM.
At the time of IM withdrawal and during IFN maintenance therapy
myeloblastin (proteinase-3, PR3) mRNA expression was determined and
compared to glucose-6-phosphate dehydrogenase transcripts as internal
standard. During IFN monotherapy, median ratios PR3/G6PD increased
from 0.06% (range, 0.02-3.5) to 0.14% (0.03-1.4; p=0.03). IFN response
was associated with the detection of autoreactive PR3 specific T-
lymphocytes during IFN maintenance therapy determined by a tetramer
assay in 7/8 patients, suggesting that PR3-specific cytotoxic T
lymphocytes contribute to the IFN-mediated antileukemic immunity. In
conclusion, we report a high rate of improved or continuous molecular
remissions in 17 of 20 patients (85%) on IFN monotherapy after prior
induction with IM/IFN. This suggests a previously unrecognized
beneficial role for IFN in the maintenance therapy after IM-mediated
debulking and may impact future CML therapy.
Abstract #28 appears in Blood, Volume 110, issue 11, November 16, 2007
Keywords: Chronic Myeloid Leukemia|Immunotherapy|Interferon alpha
Disclosure: Research Funding: Roche and Novartis. Membership
Information: Novartis advisory board. Off Label Use: Combination of
imatinib with pegylated IFN in CML.
Sunday, December 9, 2007 5:15 PM
On Dec 12, 12:17 pm, "kothai ramasamy"
wrote:
> hai,
> anybody in combination therpy of peg interferon and glivec have undergone
> molecuar studies?
>
> kothai
---------------------------------
You rock. That's why Blockbuster's offering you one month of Blockbuster Total
Access, No Cost.
--~--~---------~--~----~------------~-------~--~----~
[CMLHope]
A support group of http://cmlhope.com
-------------------------------------------------
You received this message because you are subscribed to the Google Groups
"CMLHope" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at http://groups.google.com/group/CMLHope
-~----------~----~----~----~------~----~------~--~---
